Lei Liu

Dr. Lei Liu


Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
4 September 2023 in Frontiers in Physiology
Verified
Journal Article
Open access
XCXin Chen
Xin Chen
JZJiexin Zhang
Jiexin Zhang
YLYuan Lin
Yuan Lin
YLYan Li
Yan Li
HWHan Wang
Han Wang
LLLei Liu
Lei Liu
Hypobaric hypoxia (HH) characteristics induce impaired cognitive function, reduced concentration, and memory. In recent years, an increasing number of people have migrated to high-altitude areas for work and study. Headache, sleep disturbance, and cognitive impairment from HH, severely challenges the physical and mental health and affects their quality of life and work efficiency. This review summarizes the manifestations, mechanisms, and preventive and therapeutic methods of HH environment affecting cognitive function and provides theoretical references for exploring and treating high altitude-induced cognitive impairment.

2 July 2021 in Cancer Cell International
Verified
Journal Article
Open access
PDF file
LLLei Liu
Lei Liu
HPHonglin Pang
Honglin Pang
QHQiao He
Qiao He
BPBiran Pan
Biran Pan
XSXiaobin Sun
Xiaobin Sun
YGYuanbiao Guo
Yuanbiao Guo
Background: Gastric cancer (GC) is one of the most common cancer worldwide. It is essential to identify non-invasive diagnostic and prognostic biomarkers of GC. The aim of the present study was to screen candidate biomarkers associated with the pathogenesis and prognosis of GC by a novel strategy. Methods: The expression level of gene higher in cancer than in adjacent non-cancer tissue was defined as “positive”, and the top 5% genes with “positive rate” were filtered out as candidate diagnostic biomarkers in three Gene Expression Omnibus (GEO) datasets. Further, a prognostic risk model was constructed by multivariate Cox regression analysis in GEO dataset and validated in The Cancer Genome Atlas (TCGA). The expression level of candidate biomarkers was determined in serum and serum-derived exosomes of GC patients. Moreover, the effect of biomarkers in exosomes on migration of GC cells was analyzed by transwell assay. Results: Ten candidate biomarkers (AGT, SERPINH1, WNT2, LIPG, PLAU, COL1A1, MMP7, MXRA5, CXCL1 and COL11A1) were identified with efficient diagnostic value in GC. A prognostic gene signature consisted of AGT, SERPINH1 and MMP7 was constructed and showed a good performance in predicting overall survivals in TCGA. Consistently, serum levels of the three biomarkers also showed high sensitivity and specificity in distinguishing GC patients from controls. In addition, the expression level of the three biomarkers were associated with malignant degree and decreased after surgery in GC patients. Moreover, the expression level of AGT and MMP7 in exosomes correlated positively with serum level. The exosomes derived from serum of GC patients can promote migration of SGC‐7901 cells. After neutralized the expression level of three proteins in exosomes with antibodies, the migration of GC cells was obviously suppressed. Conclusions: Our findings provided a novel strategy to identify diagnostic biomarkers based on public datasets, and suggested that the three-gene signature was a candidate diagnostic and prognostic biomarker for patients with GC.

29 April 2020 in Cancer Science
Verified
Journal Article
Open access
PDF file
TZTongtong Zhang
Tongtong Zhang
ZWZheng Wang
Zheng Wang
YLYanjun Liu
Yanjun Liu
YHYongxu Huo
Yongxu Huo
HLHongtao Liu
Hongtao Liu
YGYuanbiao Guo
Yuanbiao Guo
Tumor metastasis is the dominant cause of death in colorectal cancer (CRC) patients, and it often involves dysregulation of various cytoskeletal proteins. Plastin 1 (PLS1) is an actin‐bundling protein that has been implicated in the structure of intestinal epithelial microvilli; however, its role in CRC metastasis has not yet been determined. In this study, we demonstrated that PLS1 is highly expressed in 33.3% (45/135) of CRC patients and is correlated with lymph node metastasis and poor survival. In in vitro and in vivo experiments, PLS1 induced the migration and invasion of CRC cells and the metastases to the liver and lung in mice. Moreover, the expressions of key factors for CRC metastases, matrix metalloproteinase (MMP) 9 and 2, were enhanced by PLS1, which was dependent on phosphorylating ERK1/2 activated by IQGAP1/Rac1 signaling. The connection between these signals and PLS1 was further confirmed in CRC tissues of patients and the metastatic nodules from a mouse model. These findings suggest that PLS1 promotes CRC metastasis through the IQGAP1/Rac1/ERK pathway. Targeting PLS1 may provide a potential approach to inhibit the metastasis of CRC cells.

1 June 2022 in Clinical and Translational Oncology
Verified
Journal Article
Closed access
PDF file
LLLei Liu
Lei Liu
YHYecai Huang
Yecai Huang
YLYan Li
Yan Li
QWQiong Wang
Qiong Wang
YHYaying Hao
Yaying Hao
YGYuanbiao Guo
Yuanbiao Guo

29 December 2022 in Pharmaceuticals
Verified
Journal Article
Open access
PDF file
YSYueshan Sun
Yueshan Sun
HLHong Li
Hong Li
LLLei Liu
Lei Liu
XBXiaoqin Bai
Xiaoqin Bai
LWLiping Wu
Liping Wu
YGYuanbiao Guo
Yuanbiao Guo
Mast cell (MC) plays a central role in intestinal permeability; however, few MC-targeting drugs are currently available for protection of the intestinal barrier in clinical practice. A nonfluorinated Lidocaine analog 2-diethylamino-N-2,5-dimethylphenyl acetamide (JM25-1) displays anti-allergic effect, but its impact on MC remains elusive. In this study, we explored whether JM25-1 has therapeutic potential on intestinal barrier defect through stabilizing MC. JM25-1 alleviated release of β-hexosaminidase and cytokine production of MC. The paracellular permeability was redressed by JM25-1 in intestinal epithelial cell monolayers co-cultured with activated MC. In vivo, JM25-1 diminished intestinal mucosal MC amount and cytokine production, especially downregulating the expression of CRHR1, accompanied by an increase of CRHR2. Protective effects appeared in JM25-1-treated stress rats with a recovery of weight and intestinal barrier integrity. Through network pharmacology analysis, JM25-1 showed a therapeutic possibility for irritable bowel syndrome (IBS) with predictive targeting on PI3K/AKT/mTOR signaling. As expected, JM25-1 reinforced p-PI3K, p-AKT, p-mTOR signaling in MC, while the mTOR inhibitor Rapamycin reversed the action of JM25-1 on the expression of CRHR1 and CRHR2. Moreover, JM25-1 successfully remedied intestinal defect and declined MC and CRHR1 expression in rat colon caused by colonic mucus of IBS patients. Our data implied that JM25-1 possessed therapeutic capacity against intestinal barrier defects by targeting the CRH receptors of MC through PI3K/AKT/mTOR signaling.

12 April 2023 in Frontiers in Bioengineering and Biotechnology
Verified
Journal Article
Open access
XYXue Yao
Xue Yao
BLBaixue Liao
Baixue Liao
FCFeng Chen
Feng Chen
LLLüye Liu
Lüye Liu
KWKaiwen Wu
Kaiwen Wu
YGYuanbiao Guo
Yuanbiao Guo
Graphical In our study, three methods were used for isolating extracellular vesicles derived from pleural effusion (pEVs), including ultracentrifugation (UC), a combination of UC and size exclusion chromatography (UC-SEC) and a combination of UC and density gradient ultracentrifugation (UC-DGU), and followed with proteomics analysis. Our results show that the method of UC-SEC could significantly improve the purity of pEVs and improve the performance of proteomic analysis of pEVs. The exosomal proteins CD11C, HLA DPA1 and HLA DRB1 may act as potential markers of pEVs.